340B and Pharmaceutical Access
The 340B Drug Pricing Program supports safety net providers, such as children's hospitals, in their mission to serve low-income, uninsured and under-insured patients.
Summary of Laboratory Developed Tests Final Rule
Children's Hospital Association sent a letter to Energy and Commerce leaders supporting pediatric-focused legislation included in a recent markup.
CHA Submits Energy and Commerce Committee Statement on Oversight of the 340B Drug Pricing Program
Children's Hospital Association urges the committee to work with provider stakeholders to enhance the effectiveness and integrity of the program for children's health.
Addressing Pediatric Drug and Supply Shortages
Children’s hospitals depend on a reliable and safe drug and supply chain to provide life-saving treatments to their pediatric patients.
CHA Comments on Stimulant Medication Shortages
Children’s health groups are asking HHS and the DEA to convene stakeholders to identify actionable solutions about ongoing stimulant medication shortages.
CHA Responds to 340B Draft Bill and Request for Information
The 340B program supports children’s hospitals in their mission to serve low-income and underinsured children regardless of their insurance status.
CHA Response to Drug Shortages White Paper
CHA submitted comments on a drug shortages white paper to highlight pediatric health care needs.
CHA Response to Cell and Gene Therapy RFI
Cell and gene therapies have the potential to address unmet pediatric medical needs, reduce the need for costly chronic care, and help address health disparities.
CHA Submits Comments for Energy and Commerce Discussion Draft on Drug Shortages
CHA submitted a comment letter to the Energy and Commerce Committee to highlight pediatric needs when addressing drug shortages.
CHA Responds to Drug Shortages Request for Information
CHA submitted a response to the bicameral drug shortages request for information (RFI) to highlight pediatric health care needs.
For the Record
View CHA communications to federal policymakers such as statements for the record, RFI responses, regulatory comment letters and more.